CL2010000786A1 - Anticuerpo monoclonal anti integrina alfavbeta6 que inhibe la union de alfavbeta6 al peptido asociado a latencia (pal); composicion; uso para tratar fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; método in vitro y hibridoma con nº de acceso atcc pta-3647. (divisional sol.513-03) - Google Patents
Anticuerpo monoclonal anti integrina alfavbeta6 que inhibe la union de alfavbeta6 al peptido asociado a latencia (pal); composicion; uso para tratar fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; método in vitro y hibridoma con nº de acceso atcc pta-3647. (divisional sol.513-03)Info
- Publication number
- CL2010000786A1 CL2010000786A1 CL2010000786A CL2010000786A CL2010000786A1 CL 2010000786 A1 CL2010000786 A1 CL 2010000786A1 CL 2010000786 A CL2010000786 A CL 2010000786A CL 2010000786 A CL2010000786 A CL 2010000786A CL 2010000786 A1 CL2010000786 A1 CL 2010000786A1
- Authority
- CL
- Chile
- Prior art keywords
- integrin
- hybridoma
- alpont
- psoriasis
- syndrome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1066—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
Abstract
ANTICUERPO AISLADO O FRAGMENTO QUE ENLAZA ANTÍGENO QUE SE UNE A LA INTEGRINA AV136, QUE COMPRENDE LAS MISMAS REGIONES QUE DETERMINAN COMPLEMENTARIEDAD DE CADENA PESADA Y LIVIANA QUE UN ANTICUERPO PRODUCIDO POR EL HIBRIDOMA CON NÚMERO DE ACCESO ATCC PTA-3647, EN DONDE EL ANTICUERPO O FRAGMENTO QUE UNE ANTÍGENO DEL MISMO: PUEDE SER INTERNALIZADO POR UNA CÉLULA SW480 TRANSFECTADA POR 136; REQUIERE UN CATIÓN DIVALENTE PARA UNIRSE A AV136, PERO NO DIFERENCIA ENTRE CA 27MG2 Y MN2 ; COMPOSICIÓN; USO PARA TRATAR FIBROSIS, PSORIASIS, CÁNCER, DAÑO AGUDO DE PULMÓN O SÍNDROME DE ALPONT; MÉTODO <em>IN VITRO </em>PARA INHIBIR EL CRECIMIENTO DE CÉLULAS CANCERÍGENAS QUE EXPRESAN LA INTEGRINA AV136 Y CÉLULA DE HIBRIDOMA 6.1A8 CON N2 DE ACCESO ATCC PTA-3647.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36499102P | 2002-03-13 | 2002-03-13 | |
US42628602P | 2002-11-13 | 2002-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2010000786A1 true CL2010000786A1 (es) | 2011-02-18 |
Family
ID=29586753
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2010000788A CL2010000788A1 (es) | 2002-03-13 | 2010-07-23 | Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion farmaceutica que lo comprende; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon y sindrome de alpont; uso para detectar integrina alfa-v-beta-6 (div. sol. no. 513-03). |
CL2010000791A CL2010000791A1 (es) | 2002-03-13 | 2010-07-23 | Anticuerpo monoclonales que se unen a integrina alfavbeta6 (7.7g5), composicion; hibridoma que lo produce (atcc pta-3899); usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros. (divisional solicitud n° 513-03) |
CL2010000785A CL2010000785A1 (es) | 2002-03-13 | 2010-07-23 | Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; hibridoma (atcc pta-3645); metodo in vitro para inhibir el crecimiento de una celula cancerigena (divisional de la solicitud n° 513-03). |
CL2010000787A CL2010000787A1 (es) | 2002-03-13 | 2010-07-23 | Anticuerpo monoclonal que se une a integrina alfa-v-beta-6 (atcc pta-3896); composicion farmaceutica que lo comprende; hibridoma que lo produce; util para tratar enfermedades mediadas por dicha integrina como fibrosis, psoriasis, cancer y otros trastornos. (divisional solicitud n° 513-03) |
CL2010000789A CL2010000789A1 (es) | 2002-03-13 | 2010-07-23 | Anticuerpo monoclonal anti integrina alfabeta6, que inhibe la union de alfav-beta-6al peptido asociado a latencia (pal); composicion; uso para tratar fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; uso para deteccion de alfa-vbetas; hibridoma con n° de acceso atcc pta-3646 (div.sol.no. 513-03) |
CL2010000792A CL2010000792A1 (es) | 2002-03-13 | 2010-07-23 | Anticuerpo monoclonal que se une a integrina alfavbeta6 o fragmento que enlaza a antigeno que comprende los mismos cdr que un anticuerpo producido por el hibridoma 7.1c5 (numero de acceso atcc pta-3900); composicion farmaceutica que lo comprende; hibridoma; y su uso (div.sol.no.513-03). |
CL2010000786A CL2010000786A1 (es) | 2002-03-13 | 2010-07-23 | Anticuerpo monoclonal anti integrina alfavbeta6 que inhibe la union de alfavbeta6 al peptido asociado a latencia (pal); composicion; uso para tratar fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; método in vitro y hibridoma con nº de acceso atcc pta-3647. (divisional sol.513-03) |
CL2010000790A CL2010000790A1 (es) | 2002-03-13 | 2010-07-23 | Anticuerpos monoclonales que se unen a integrina alfa-nu-beta6 (atcc pta-3898) composicion; hibridoma que lo produce; usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros (div.sol.no. 513-03). |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2010000788A CL2010000788A1 (es) | 2002-03-13 | 2010-07-23 | Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion farmaceutica que lo comprende; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon y sindrome de alpont; uso para detectar integrina alfa-v-beta-6 (div. sol. no. 513-03). |
CL2010000791A CL2010000791A1 (es) | 2002-03-13 | 2010-07-23 | Anticuerpo monoclonales que se unen a integrina alfavbeta6 (7.7g5), composicion; hibridoma que lo produce (atcc pta-3899); usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros. (divisional solicitud n° 513-03) |
CL2010000785A CL2010000785A1 (es) | 2002-03-13 | 2010-07-23 | Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; hibridoma (atcc pta-3645); metodo in vitro para inhibir el crecimiento de una celula cancerigena (divisional de la solicitud n° 513-03). |
CL2010000787A CL2010000787A1 (es) | 2002-03-13 | 2010-07-23 | Anticuerpo monoclonal que se une a integrina alfa-v-beta-6 (atcc pta-3896); composicion farmaceutica que lo comprende; hibridoma que lo produce; util para tratar enfermedades mediadas por dicha integrina como fibrosis, psoriasis, cancer y otros trastornos. (divisional solicitud n° 513-03) |
CL2010000789A CL2010000789A1 (es) | 2002-03-13 | 2010-07-23 | Anticuerpo monoclonal anti integrina alfabeta6, que inhibe la union de alfav-beta-6al peptido asociado a latencia (pal); composicion; uso para tratar fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; uso para deteccion de alfa-vbetas; hibridoma con n° de acceso atcc pta-3646 (div.sol.no. 513-03) |
CL2010000792A CL2010000792A1 (es) | 2002-03-13 | 2010-07-23 | Anticuerpo monoclonal que se une a integrina alfavbeta6 o fragmento que enlaza a antigeno que comprende los mismos cdr que un anticuerpo producido por el hibridoma 7.1c5 (numero de acceso atcc pta-3900); composicion farmaceutica que lo comprende; hibridoma; y su uso (div.sol.no.513-03). |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2010000790A CL2010000790A1 (es) | 2002-03-13 | 2010-07-23 | Anticuerpos monoclonales que se unen a integrina alfa-nu-beta6 (atcc pta-3898) composicion; hibridoma que lo produce; usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros (div.sol.no. 513-03). |
Country Status (23)
Country | Link |
---|---|
US (4) | US7465449B2 (es) |
EP (4) | EP1490110B1 (es) |
JP (6) | JP4473117B2 (es) |
KR (1) | KR101098109B1 (es) |
CN (4) | CN102659946A (es) |
AR (1) | AR038970A1 (es) |
AU (1) | AU2003261071C1 (es) |
BR (1) | BRPI0308585B8 (es) |
CA (1) | CA2478833C (es) |
CL (8) | CL2010000788A1 (es) |
EA (1) | EA011853B1 (es) |
ES (1) | ES2389037T3 (es) |
HK (2) | HK1074381A1 (es) |
IL (4) | IL164021A0 (es) |
IS (1) | IS7443A (es) |
ME (1) | ME00804B (es) |
MX (1) | MXPA04008870A (es) |
MY (2) | MY147019A (es) |
NO (1) | NO334834B1 (es) |
NZ (2) | NZ535425A (es) |
PL (1) | PL216223B1 (es) |
RS (1) | RS52488B (es) |
WO (1) | WO2003100033A2 (es) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA011853B1 (ru) | 2002-03-13 | 2009-06-30 | Байоджен Айдек Ма Инк. | АНТИТЕЛА ПРОТИВ αβ |
JP2006506323A (ja) * | 2002-04-12 | 2006-02-23 | レイヴェン バイオテクノロジーズ, インコーポレイテッド | インテグリンα−v−β−6に結合する抗体およびその使用方法 |
CA2434668A1 (en) * | 2003-07-04 | 2005-01-04 | Laurence Mulard | Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a |
AU2012258386B2 (en) * | 2005-07-08 | 2014-08-07 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
CN102875681A (zh) * | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
US20100267060A1 (en) * | 2006-01-17 | 2010-10-21 | Biosite Incorporated | High sensitivity secretagogin assays and their uses for diagnosis and/or prognosis |
BRPI0714381A2 (pt) * | 2006-07-10 | 2013-03-05 | Biogen Idec Inc | composiÇÕes e mÉtodos para inibir crescimento de cÂnceres deficientes em smad4 |
CA2658612C (en) * | 2006-08-03 | 2015-11-17 | Astrazeneca Ab | Antibodies directed to .alpha.v.beta.6 and uses thereof |
CA2665885A1 (en) * | 2006-10-19 | 2008-12-04 | The Regents Of The University Of California | Treatment and prevention of chronic asthma using antagonists of integrin .alpha.nu.beta.6 |
US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
US20110064744A1 (en) * | 2007-05-30 | 2011-03-17 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
DK2164992T3 (en) * | 2007-05-30 | 2016-08-15 | Lpath Inc | COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID |
PL2207568T3 (pl) | 2007-11-16 | 2018-01-31 | Univ Rockefeller | Przeciwciała specyficzne względem postaci protofibrylarnej białka beta-amyloidu |
ES2549903T3 (es) | 2008-05-07 | 2015-11-03 | Argos Therapeutics, Inc. | Anticuerpos humanizados contra interferón alfa humano |
AU2009245724A1 (en) * | 2008-05-09 | 2009-11-12 | Ablynx N.V. | Amino acid sequences directed against integrins and uses thereof |
EP2285989B1 (en) * | 2008-05-15 | 2016-11-16 | The University of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
CA2998281C (en) | 2008-09-26 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1 antobodies and uses therefor |
PT2467401T (pt) | 2009-08-19 | 2017-04-26 | Merck Patent Gmbh | Anticorpos para a deteção de complexos de integrina em material ffpe |
WO2011119524A1 (en) * | 2010-03-22 | 2011-09-29 | The University Of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
CA2797856C (en) | 2010-04-30 | 2018-09-18 | Alexion Pharmaceuticals, Inc. | Anti-c5a antibodies and methods for using the antibodies |
EP2699268A2 (de) | 2011-04-21 | 2014-02-26 | Seattle Genetics, Inc. | Neue binder-wirkstoff konjugate (adcs) und ihre verwendung |
US8852592B2 (en) | 2011-05-10 | 2014-10-07 | Biocare Medical, Llc | Systems and methods for anti-PAX8 antibodies |
CN105017420B (zh) | 2012-02-17 | 2019-05-28 | 西雅图基因公司 | 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症 |
US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
ES2682345T3 (es) | 2012-09-27 | 2018-09-20 | Biocare Medical, Llc | Sistemas y procedimientos de anticuerpos antiuroplaquina II |
PT2905335T (pt) * | 2012-10-03 | 2018-03-12 | Chiome Bioscience Inc | Anticorpo anti-hdlk-1 tendo uma atividade anti-tumoral in vivo |
CN104837502B (zh) | 2012-10-12 | 2018-08-10 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
WO2014100220A2 (en) | 2012-12-18 | 2014-06-26 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
WO2014134587A1 (en) | 2013-02-28 | 2014-09-04 | Biocare Medical, Llc | Anti-p40 antibodies systems and methods |
ES2687439T3 (es) | 2013-03-13 | 2018-10-25 | Medimmune Limited | Pirrolobenzodiazepinas y conjugados de las mismas |
WO2014144466A1 (en) * | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
WO2014143739A2 (en) * | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
AU2014312086B2 (en) * | 2013-08-30 | 2020-03-12 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
KR102150616B1 (ko) | 2013-09-12 | 2020-09-03 | 삼성전자주식회사 | c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도 |
EP3052523B1 (en) * | 2013-10-01 | 2021-03-10 | Medimmune Limited | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
JP6506267B2 (ja) | 2013-10-03 | 2019-04-24 | バイオケア メディカル, エルエルシー | 抗sox10抗体のシステムおよび方法 |
CN104721225A (zh) | 2013-12-19 | 2015-06-24 | 高露洁-棕榄公司 | 口腔护理组合物 |
RU2698697C2 (ru) | 2013-12-23 | 2019-08-29 | Байер Фарма Акциенгезельшафт | Конъюгаты связующего (ADC) с ингибиторами KSP |
EP3102611A4 (en) * | 2014-02-03 | 2017-08-23 | Cangene Corporation | Humanized beta-amyloid binding molecules and uses thereof |
SG10201913680PA (en) | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
SG10201908685QA (en) | 2015-06-22 | 2019-10-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
CN107921288A (zh) | 2015-06-23 | 2018-04-17 | 拜耳医药股份有限公司 | Ksp抑制剂的靶向缀合物 |
EP3334453A4 (en) * | 2015-08-13 | 2019-02-06 | New York University | SPECIFIC ANTIBODY MOLECULES OF THE ASP421 EPITOPE TRUNCATED FROM THE TAU PROTEIN AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY |
MA42844A (fr) | 2015-09-17 | 2018-07-25 | Immunogen Inc | Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1 |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
MX2018011627A (es) | 2016-03-24 | 2019-01-10 | Bayer Pharma AG | Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles. |
CN109310781A (zh) | 2016-06-15 | 2019-02-05 | 拜耳制药股份公司 | 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc) |
WO2018017797A1 (en) * | 2016-07-22 | 2018-01-25 | Georgia State Universtiy Research Foundation | Monoclonal antibodies to b virus and their use for identification of b virus specific reactive peptides |
EP3525829A1 (en) | 2016-10-11 | 2019-08-21 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
EP3538104A1 (en) | 2016-11-08 | 2019-09-18 | Reata Pharmaceuticals, Inc. | Methods of treating alport syndrome using bardoxolone methyl or analogs thereof |
EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
CA3045931A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
US11433140B2 (en) | 2016-12-21 | 2022-09-06 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (ADCs) having KSP inhibitors |
CA3047491A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
US11660351B2 (en) | 2016-12-21 | 2023-05-30 | Bayer Aktiengesellschaft | Antibody drug conjugates (ADCs) having enzymatically cleavable groups |
GB201720989D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
JP7350061B2 (ja) | 2018-05-11 | 2023-10-02 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | フューリンインヒビター |
SG11202010469QA (en) | 2018-05-23 | 2020-11-27 | Adc Therapeutics Sa | Molecular adjuvant |
EP3810085A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
US20230023414A1 (en) | 2018-11-19 | 2023-01-26 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
GB201908536D0 (en) | 2019-06-13 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Compounds |
EP4065167A4 (en) * | 2019-11-26 | 2024-03-27 | Childrens Hospital Med Ct | INHIBITION OF CELA-1 FOR THE TREATMENT OF PULMONARY DISEASE |
CA3159414A1 (en) | 2019-12-05 | 2021-06-10 | Seagen Inc. | Anti-av.beta.6 antibodies and antibody-drug conjugates |
US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
WO2022164816A1 (en) * | 2021-01-26 | 2022-08-04 | The Regents Of The University Of California | Compositions and methods for treating and preventing disease associated with avb8 integrin |
EP4288052A1 (en) | 2021-02-03 | 2023-12-13 | BP Asset V, Inc. | Formulation of furin inhibitor for inhalation |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
WO2023194895A1 (en) | 2022-04-06 | 2023-10-12 | Glaxosmithkline Intellectual Property Development Limited | Pyrrol derivatives as inhibitors of apolipoprotein l-1 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US5223493A (en) | 1984-12-28 | 1993-06-29 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
NZ222509A (en) | 1986-11-19 | 1993-03-26 | Oncogen | Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen |
US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5804381A (en) * | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9009549D0 (en) * | 1990-04-27 | 1990-06-20 | Celltech Ltd | Recombinant antibody and method |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
US5962643A (en) | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
PL174721B1 (pl) | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
US6307026B1 (en) | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
US5420120A (en) | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6417324B1 (en) * | 2000-04-21 | 2002-07-09 | Tripep Ab | Synthetic peptides that bind to the hepatitis B virus core and e antigens |
ES2202336T3 (es) * | 1994-12-20 | 2004-04-01 | Merck Patent Gmbh | Anticuerpo monoclonal contra la integrina alfa-v. |
US5719156A (en) | 1995-05-02 | 1998-02-17 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US5696267A (en) | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
US5795894A (en) | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
US5688960A (en) | 1995-05-02 | 1997-11-18 | Schering Corporation | Substituted oximes, hydrazones and olefins useful as neurokinin antagonists |
US5654316A (en) | 1995-06-06 | 1997-08-05 | Schering Corporation | Piperidine derivatives as neurokinin antagonists |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
WO1997006822A1 (en) | 1995-08-17 | 1997-02-27 | Protein Design Labs, Inc. | Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage |
DK0859841T3 (da) | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein/(poly)peptidbiblioteker |
KR100308764B1 (ko) | 1995-08-29 | 2001-12-17 | 마나배게이사꾸 | 키메라동물및그의제작법 |
US5691362A (en) | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
CA2257357C (en) * | 1996-06-07 | 2010-04-13 | Neorx Corporation | Humanized antibodies with modified glycosylation |
WO1998006839A1 (en) | 1996-07-15 | 1998-02-19 | Human Genome Sciences, Inc. | Cd44-like protein |
US5789422A (en) | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
US5783579A (en) | 1996-12-20 | 1998-07-21 | Schering Corporation | Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists |
PL201716B1 (pl) | 1997-08-08 | 2009-05-29 | Univ California | Zastosowanie przeciwciała specyficznie wiążącego się do integryny alfa 6 w leczeniu zwłóknienia wątroby |
HUP0101151A3 (en) | 1998-01-23 | 2004-06-28 | Merck Patent Gmbh | Monoclonal antibody anti alphav-integrin and its use to inhibit alphavbetha6-integrin attachment to fibnronectin |
CN1335853A (zh) | 1998-12-19 | 2002-02-13 | 默克专利股份公司 | 整联蛋白αvβb的抑制剂 |
US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
DE10063173A1 (de) | 2000-12-18 | 2002-06-20 | Merck Patent Gmbh | Harnstoff- und Urethanderivate |
AU2002258778C1 (en) | 2001-04-13 | 2008-12-04 | Biogen Ma Inc. | Antibodies to VLA-1 |
DE10118550A1 (de) | 2001-04-14 | 2002-10-17 | Merck Patent Gmbh | Liganden des Integrins alpha¶nu¶beta¶6¶ |
GB2380127A (en) | 2001-09-26 | 2003-04-02 | Isis Innovation | Treatment of chronic joint inflammation |
MXPA04008267A (es) | 2002-02-25 | 2004-11-10 | Elan Pharm Inc | Administracion de agentes para el tratamiento de la inflamacion. |
EA011853B1 (ru) | 2002-03-13 | 2009-06-30 | Байоджен Айдек Ма Инк. | АНТИТЕЛА ПРОТИВ αβ |
JP2006506323A (ja) | 2002-04-12 | 2006-02-23 | レイヴェン バイオテクノロジーズ, インコーポレイテッド | インテグリンα−v−β−6に結合する抗体およびその使用方法 |
EP1511738A4 (en) | 2002-05-17 | 2007-05-09 | Scios Inc | TREATMENT OF FIBROPROLIFERATIVE DISEASES USING TGF BETA INHIBITORS |
CN100369930C (zh) | 2002-11-26 | 2008-02-20 | Pdl生物制药股份有限公司 | 调节血管生成的α5β1整合素的嵌合的和人源化的抗体 |
US20040253311A1 (en) | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
CA2540730C (en) | 2003-10-01 | 2012-08-21 | Merck Patent Gmbh | Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents |
US20070292887A1 (en) | 2003-11-04 | 2007-12-20 | Bayer Pharmaceuticals Corporation | Immunohistochemical Methods |
CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
BRPI0714381A2 (pt) | 2006-07-10 | 2013-03-05 | Biogen Idec Inc | composiÇÕes e mÉtodos para inibir crescimento de cÂnceres deficientes em smad4 |
CA2665885A1 (en) | 2006-10-19 | 2008-12-04 | The Regents Of The University Of California | Treatment and prevention of chronic asthma using antagonists of integrin .alpha.nu.beta.6 |
GB0803192D0 (en) | 2008-02-22 | 2008-04-02 | Mubio Products Bv | SCLC biomarker panel |
CN102265156B (zh) | 2008-12-23 | 2014-11-05 | 默克专利有限公司 | 用于具有抗血管发生活性的抑制剂的生物标志 |
WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
EP2831104B1 (en) | 2012-03-29 | 2021-04-21 | Biogen MA Inc. | Biomarkers for use in integrin therapy applications |
-
2003
- 2003-03-13 EA EA200401198A patent/EA011853B1/ru unknown
- 2003-03-13 KR KR1020047014307A patent/KR101098109B1/ko active IP Right Grant
- 2003-03-13 MY MYPI20030886A patent/MY147019A/en unknown
- 2003-03-13 EP EP03755325A patent/EP1490110B1/en not_active Expired - Lifetime
- 2003-03-13 AR ARP030100885A patent/AR038970A1/es not_active Application Discontinuation
- 2003-03-13 BR BRPI0308585A patent/BRPI0308585B8/pt not_active IP Right Cessation
- 2003-03-13 MY MYPI20094390A patent/MY154009A/en unknown
- 2003-03-13 CN CN2012100664380A patent/CN102659946A/zh active Pending
- 2003-03-13 MX MXPA04008870A patent/MXPA04008870A/es active IP Right Grant
- 2003-03-13 JP JP2004508275A patent/JP4473117B2/ja not_active Expired - Fee Related
- 2003-03-13 CN CNA038089068A patent/CN1646160A/zh active Pending
- 2003-03-13 NZ NZ535425A patent/NZ535425A/en not_active IP Right Cessation
- 2003-03-13 ME MEP-2009-200A patent/ME00804B/me unknown
- 2003-03-13 AU AU2003261071A patent/AU2003261071C1/en not_active Expired
- 2003-03-13 IL IL16402103A patent/IL164021A0/xx unknown
- 2003-03-13 WO PCT/US2003/008048 patent/WO2003100033A2/en active Application Filing
- 2003-03-13 EP EP10012545A patent/EP2336185A1/en not_active Withdrawn
- 2003-03-13 CN CN201510182148.6A patent/CN104805090A/zh active Pending
- 2003-03-13 EP EP10013156.4A patent/EP2287199B1/en not_active Expired - Lifetime
- 2003-03-13 RS YU80704A patent/RS52488B/en unknown
- 2003-03-13 CA CA2478833A patent/CA2478833C/en not_active Expired - Lifetime
- 2003-03-13 EP EP10013155A patent/EP2287198A3/en not_active Ceased
- 2003-03-13 CN CN201210067222.6A patent/CN102924598B/zh not_active Expired - Lifetime
- 2003-03-13 PL PL372662A patent/PL216223B1/pl unknown
- 2003-03-13 ES ES03755325T patent/ES2389037T3/es not_active Expired - Lifetime
- 2003-03-13 US US10/507,662 patent/US7465449B2/en not_active Expired - Lifetime
- 2003-12-13 NZ NZ563951A patent/NZ563951A/en not_active IP Right Cessation
-
2004
- 2004-09-09 IS IS7443A patent/IS7443A/is unknown
- 2004-09-12 IL IL164021A patent/IL164021A/en active IP Right Grant
- 2004-09-12 IL IL225633A patent/IL225633B/en unknown
- 2004-10-13 NO NO20044347A patent/NO334834B1/no not_active IP Right Cessation
-
2005
- 2005-06-28 HK HK05105402.6A patent/HK1074381A1/xx not_active IP Right Cessation
-
2008
- 2008-10-29 US US12/260,510 patent/US8153126B2/en not_active Expired - Lifetime
-
2009
- 2009-01-21 JP JP2009011451A patent/JP2009100763A/ja not_active Withdrawn
-
2010
- 2010-07-23 CL CL2010000788A patent/CL2010000788A1/es unknown
- 2010-07-23 CL CL2010000791A patent/CL2010000791A1/es unknown
- 2010-07-23 CL CL2010000785A patent/CL2010000785A1/es unknown
- 2010-07-23 CL CL2010000787A patent/CL2010000787A1/es unknown
- 2010-07-23 CL CL2010000789A patent/CL2010000789A1/es unknown
- 2010-07-23 CL CL2010000792A patent/CL2010000792A1/es unknown
- 2010-07-23 CL CL2010000786A patent/CL2010000786A1/es unknown
- 2010-07-23 CL CL2010000790A patent/CL2010000790A1/es unknown
-
2012
- 2012-04-10 US US13/443,261 patent/US20120251532A1/en not_active Abandoned
- 2012-08-09 JP JP2012177348A patent/JP5616932B2/ja not_active Expired - Lifetime
- 2012-08-09 JP JP2012177349A patent/JP2012228269A/ja not_active Withdrawn
-
2013
- 2013-04-08 IL IL225633A patent/IL225633A0/en unknown
-
2014
- 2014-07-28 US US14/444,701 patent/US9745376B2/en not_active Expired - Lifetime
- 2014-11-19 JP JP2014234208A patent/JP2015091807A/ja not_active Withdrawn
-
2015
- 2015-03-11 JP JP2015048289A patent/JP2015126743A/ja not_active Withdrawn
-
2016
- 2016-01-22 HK HK16100767.3A patent/HK1213007A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2010000786A1 (es) | Anticuerpo monoclonal anti integrina alfavbeta6 que inhibe la union de alfavbeta6 al peptido asociado a latencia (pal); composicion; uso para tratar fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; método in vitro y hibridoma con nº de acceso atcc pta-3647. (divisional sol.513-03) | |
HK1072272A1 (en) | Anti-ccr5 antibody | |
AR085874A2 (es) | Un anticuerpo monoclonal o un fragmento del mismo que se une a un antigeno | |
DE60116753D1 (de) | Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor | |
PE20211707A1 (es) | Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrp | |
CU22997A3 (es) | Proteína híbrida para la inhibición de la desgranulación de los mastocitos y su utilización | |
CO6231000A2 (es) | Anticuerpos contra de erbb3 y usos de los mismos | |
AR075790A2 (es) | Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural) | |
NZ548325A (en) | Mutants of anti-CD40 antibody | |
CO4480111A1 (es) | Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes | |
CO5660296A2 (es) | Anticuerpos humanizados que reconocen el peptido beta amiloide | |
IL193212A0 (en) | Anti-idiotypic antibody which neutralizes the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii | |
LT2005099A (en) | Antibodies directed to monoclonal chemo-atractant protein-1 (mcp-1) and uses thereof | |
EP4063497A4 (en) | ANTI-IMP TYPE CARBAPENEMASE HYBRIDOME CELL STEM, MONOCLONAL ANTIBODY AND USE | |
AR011327A1 (es) | Un producto de tisu que define una superficie principal que tiene un area de superficie planar. | |
ES2625823T3 (es) | Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo | |
AR120430A1 (es) | Células car-t dirigidas a epha3 para el tratamiento de tumores | |
RS52918B (en) | PROCEDURES AND MIXTURES FOR TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH ALFA V BETA 5 INTEGRINE | |
GB2387847B (en) | Method for producing monoclonal antibodies | |
EP1692179A4 (en) | VARIABLE REGION OF MONOCLONAL ANTIBODY DIRECTED AGAINST TUMOR NECROSIS FACTOR ALPHA HUMAN, AND GENE ENCODING THE VARIABLE REGION | |
SE0401744D0 (sv) | Containerok | |
DK1040097T3 (da) | Stoffer, som åbner kaliumkanaler | |
Ichino et al. | Molecular beam epitaxy and optical properties of ZnCdS/ZnMgS quantum wells on GaP | |
WO2023225528A3 (en) | Anti-cd84 antibodies and uses thereof | |
WO2023137364A3 (en) | Sars-cov-2 therapies |